Eurofins Scientific Shares Break Through Key Resistance, Jump Nearly 3%
The Luxembourg-based bioanalytical testing specialist registers a sharp rebound during the session, supported by a well-oriented CAC 40. The stock crosses a technical threshold monitored for several weeks, following an April marked by poorly received quarterly results.
A Rebound that Breaks the €63.24 Resistance During the Session
Eurofins Scientific shares gain 2.69% to €63.44, within a CAC 40 that is up by 0.98%. The stock is among the top gainers in the Paris index. This movement allows it to surpass the resistance identified at €63.24, a technical barrier that had contained the price for several sessions. The stock remains above this level after crossing, at €63.36 on the last check. In terms of moving averages, the rebound brings the price closer to the MM200 at €63.27, now in contact (+0.27%). The stock has already surpassed the MM20 (€60.97) and MM50 (€62.50), with a gap of +4.05% and +1.50% respectively. The RSI at 52 remains neutral, which leaves room before potentially reaching an overbought zone. The monthly progress stands at +7.5%, while the stock is still down 4% over three months.
The Stock is Still Digesting the April Downturn and Oddo BHF's Revision
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's rebound is part of a recovery movement following a poorly received quarterly publication in April, which had maintained the key support around €57.54. Last week, Oddo BHF had lowered its price target, temporarily weighing on the stock. Today’s rise partially erases this downturn and brings the annual performance to nearly 10%. The sectoral context is rather supportive, with Sanofi advancing by 2.56%. The next technical step to monitor is the consolidation above the MM200 at €63.27, whose clear crossing would pave the way for a return to the €65 zone. Conversely, a retreat below €63.24 would reposition the resistance as a short-term ceiling.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.